ZTS Valuation Metrics
ZTS Stock Price Metrics
ZTS Dividend Metrics
ZTS Growth Rate Metrics
ZTS Discounted Cash Flow Metrics
| Fair Value Price | $192.99 |
| Margin of Safety | 134.78% |
ZTS Revenue Metrics
ZTS PE Ratio Metrics
| PE Ratio | 13.63 |
| PE Ratio Avg TTM | 22.19 |
| PE Ratio Avg 3Y | 30.49 |
| Current VS TTM Avg | -38.58% |
| Current VS 3Y Avg | -55.29% |
| Current VS 5Y Avg | -61.57% |
ZTS PS Ratio Metrics
| PS Ratio | 3.65 |
| PS Ratio Avg TTM | 6.12 |
| PS Ratio Avg 3Y | 8.20 |
| Current VS TTM Avg | -40.35% |
| Current VS 3Y Avg | -55.49% |
| Current VS 5Y Avg | -61.00% |
ZTS PB Ratio Metrics
| PB Ratio | 10.74 |
| PB Ratio Avg TTM | 13.00 |
| PB Ratio Avg 3Y | 15.23 |
| Current VS TTM Avg | -17.38% |
| Current VS 3Y Avg | -29.49% |
| Current VS 5Y Avg | -35.88% |
ZTS Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 16.26 |
| PFCF Ratio Avg TTM | 25.61 |
| PFCF Ratio Avg 3Y | 39.32 |
| Current VS TTM Avg | -36.50% |
| Current VS 3Y Avg | -58.65% |
| Current VS 5Y Avg | -64.37% |
ZTS Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 2.85 |
| Debt/Equity Ratio Avg TTM | 2.13 |
| Debt/Equity Ratio Avg 3Y | 1.86 |
| Current VS TTM Avg | +33.80% |
| Current VS 3Y Avg | +53.02% |
| Current VS 5Y Avg | +57.17% |
ZTS PEG Ratio Metrics
| PEG Ratio | 2.04 |
| PEG Ratio Avg TTM | 2.04 |
| PEG Ratio Avg 3Y | 2.04 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
ZTS FCF Yield
| FCF Yield | 6.15% |
| FCF Yield Avg TTM | 4.05% |
| FCF Yield Avg 3Y | 2.89% |
| Current VS TTM Avg | +51.72% |
| Current VS 3Y Avg | +112.82% |
| Current VS 5Y Avg | +149.67% |
ZTS Earnings Yield
| Earnings Yield | 7.34% |
| Earnings Yield Avg TTM | 4.71% |
| Earnings Yield Avg 3Y | 3.52% |
| Current VS TTM Avg | +55.96% |
| Current VS 3Y Avg | +108.68% |
| Current VS 5Y Avg | +139.24% |
ZTS EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 11.76 |
| Ev/Ebit Ratio Avg TTM | 17.95 |
| Ev/Ebit Ratio Avg 3Y | 24.05 |
| Current VS TTM Avg | -34.49% |
| Current VS 3Y Avg | -51.10% |
| Current VS 5Y Avg | -57.09% |
ZTS EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 10.40 |
| Ev/Ebitda Ratio Avg TTM | 15.71 |
| Ev/Ebitda Ratio Avg 3Y | 20.70 |
| Current VS TTM Avg | -33.82% |
| Current VS 3Y Avg | -49.76% |
| Current VS 5Y Avg | -56.27% |
ZTS EV/Assets Ratio Metrics
| Ev/Assets Ratio | 2.77 |
| Ev/Assets Ratio Avg TTM | 4.27 |
| Ev/Assets Ratio Avg 3Y | 5.44 |
| Current VS TTM Avg | -35.19% |
| Current VS 3Y Avg | -49.09% |
| Current VS 5Y Avg | -52.55% |
ZTS EV/Sales Ratio Metrics
| Ev/Sales Ratio | 4.42 |
| Ev/Sales Ratio Avg TTM | 6.74 |
| Ev/Sales Ratio Avg 3Y | 8.79 |
| Current VS TTM Avg | -34.44% |
| Current VS 3Y Avg | -49.69% |
| Current VS 5Y Avg | -55.40% |
ZTS Current Ratio Metrics
| Current Ratio | 3.03 |
| Current Ratio Avg TTM | 2.39 |
| Current Ratio Avg 3Y | 2.63 |
| Current VS TTM Avg | +26.78% |
| Current VS 3Y Avg | +15.32% |
| Current VS 5Y Avg | +4.36% |
ZTS Quick Ratio Metrics
| Quick Ratio | 1.94 |
| Quick Ratio Avg TTM | 1.51 |
| Quick Ratio Avg 3Y | 1.66 |
| Current VS TTM Avg | +28.48% |
| Current VS 3Y Avg | +16.69% |
| Current VS 5Y Avg | -0.85% |
ZTS ROIC Metrics
| ROIC | 21.54% |
| ROIC Avg 3Y | 20.30% |
| ROIC Avg 5Y | 19.27% |
| Current VS 3Y Avg | +6.08% |
| Current VS 5Y Avg | +11.81% |
| Current VS 10Y Avg | +27.22% |
ZTS Return on Assets Metrics
| ROA | 17.28 |
| ROA Avg TTM | 17.37 |
| ROA Avg 3Y | 16.33 |
| Current VS TTM Avg | -0.52% |
| Current VS 3Y Avg | +5.83% |
| Current VS 5Y Avg | +12.70% |
ZTS Return on Equity Metrics
| ROE | 80.25 |
| ROE Avg TTM | 66.19 |
| ROE Avg 3Y | 56.82 |
| Current VS TTM Avg | +21.25% |
| Current VS 3Y Avg | +41.24% |
| Current VS 5Y Avg | +52.58% |
ZTS Net Profit Margin Metrics
| Net Profit Margin | 28.23% |
| Net Profit Margin Avg TTM | 27.55% |
| Net Profit Margin Avg 3Y | 27.17% |
| Current VS TTM Avg | +2.49% |
| Current VS 3Y Avg | +3.90% |
| Current VS 5Y Avg | +6.25% |
Last Updated: Tuesday, June 9, 2026
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck